NCT02173782View on ClinicalTrials.gov

Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

892

Participants

Timeline

Start Date

February 28, 1998

Primary Completion Date

April 30, 1999

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Berodual® Respimat ® high dose

DRUG

Berodual® Respimat ® low dose

DRUG

Berodual® MDI

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02173782 - Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter